Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 18989231)

1.

Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.

McCormack SA, Best BM.

Front Pediatr. 2014 Feb 11;2:9. doi: 10.3389/fped.2014.00009. eCollection 2014. Review.

2.

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F.

J Clin Pharmacol. 2014 Feb;54(2):121-32. doi: 10.1002/jcph.167. Epub 2013 Sep 21.

3.

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66. doi: 10.1097/QAI.0b013e318289b4d2.

4.

Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Vinot C, Gavard L, Tréluyer JM, Manceau S, Courbon E, Scherrmann JM, Declèves X, Duro D, Peytavin G, Mandelbrot L, Giraud C.

Antimicrob Agents Chemother. 2013 Mar;57(3):1415-20. doi: 10.1128/AAC.01821-12. Epub 2013 Jan 7.

5.

Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.

6.

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP.

Antimicrob Agents Chemother. 2012 Feb;56(2):816-24. doi: 10.1128/AAC.05186-11. Epub 2011 Nov 21.

7.

Clinical therapeutics in pregnancy.

Feghali MN, Mattison DR.

J Biomed Biotechnol. 2011;2011:783528. doi: 10.1155/2011/783528. Epub 2011 Jul 6.

8.

Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.

Achenbach CJ, Darin KM, Murphy RL, Katlama C.

Future Virol. 2011 Feb;6(2):157-177.

9.

Health needs of HIV-infected women in the United States: insights from the women living positive survey.

Squires KE, Hodder SL, Feinberg J, Bridge DA, Abrams S, Storfer SP, Aberg JA.

AIDS Patient Care STDS. 2011 May;25(5):279-85. doi: 10.1089/apc.2010.0228. Epub 2011 Mar 29.

10.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

11.

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):381-8.

12.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team.

AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

13.

Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, Ryan M, Nakabiito C, Back DJ, Khoo S, Merry C, Scarsi KK.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):345-50. doi: 10.1097/QAI.0b013e3181e9871b.

14.
15.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M.

N Engl J Med. 2010 Jun 17;362(24):2282-94. doi: 10.1056/NEJMoa0907736.

16.

Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.

Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, Hughes MD, Tuomala R.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):27-34. doi: 10.1097/QAI.0b013e3181caea89.

17.

Lopinavir protein binding in HIV-1-infected pregnant women.

Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team.

HIV Med. 2010 Apr;11(4):232-8. doi: 10.1111/j.1468-1293.2009.00767.x. Epub 2009 Dec 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk